Peking Union Medical College Hospital
北京协和医院
Listed for 42 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Peking Union Medical College Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led1 open trial led
- Hepatocellular carcinoma肝细胞癌65 papers led10 open trials led
- Stomach cancer胃癌54 papers led
- Retinoblastoma视网膜母细胞瘤0 papers led
- Osteosarcoma骨肉瘤4 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤6 papers led
- Neuroblastoma神经母细胞瘤7 papers led1 open trial led
- Ewing sarcoma尤文肉瘤1 paper led
- Multiple myeloma多发性骨髓瘤27 papers led2 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
- Aplastic anaemia再生障碍性贫血16 papers led1 open trial led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症7 papers led
- Beta thalassaemiaβ 地中海贫血1 paper led
- Haemophilia A血友病 A17 papers led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病8 papers led
- IgG4-related diseaseIgG4相关性疾病47 papers led7 open trials led
- Myasthenia gravis重症肌无力6 papers led
- Moyamoya disease烟雾病9 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
- Takayasu arteritis大动脉炎27 papers led
- Hepatic echinococcosis肝包虫病0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化18 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病14 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症44 papers led
- Spinal muscular atrophy脊髓性肌萎缩症3 papers led1 open trial led
- Fabry disease法布雷病2 papers led
- Pompe disease庞贝病1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病49 papers led2 open trials led
- IgA nephropathyIgA 肾病5 papers led
- Gaucher disease戈谢病1 paper led
- Osteogenesis imperfecta成骨不全症14 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎22 papers led1 open trial led
- Primary sclerosing cholangitis原发性硬化性胆管炎3 papers led
- Congenital diaphragmatic hernia先天性膈疝2 papers led
- Hirschsprung disease先天性巨结肠1 paper led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
- Hereditary angioedema遗传性血管性水肿10 papers led
- Majeed syndromeMajeed 综合征0 papers led
Not listed for: Hepatoblastoma, Chordoma, Fanconi anaemia, Wilson disease, Biliary atresia, Alport syndrome, Niemann–Pick disease type C, Familial adenomatous polyposis, Leber hereditary optic neuropathy, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Biomarkers for nasopharyngeal carcinoma.
- Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy.
- Tracheoesophageal Diversion and Laryngotracheal Separation Procedures for Radiotherapy-Related Intractable Aspiration Pneumonia in Nasopharyngeal Carcinoma.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)3
- Abstract 1113: USP18 impairs the sensitivity of radiotherapy for nasopharyngeal carcinoma by promoting the ubiquitination and nuclear translocation of TRIM29
- Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Open trials as a site
- 0
- led by another institution
12 hospitals in Beijing for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingOptimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06907602
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study.
- The clinical outcomes of endoscopic submucosal dissection for superficial circumferential esophageal squamous cell carcinoma may be not as ideal as expected.
- Application of intraoperative nerve monitoring for recurrent laryngeal nerves in minimally invasive McKeown esophagectomy.
- Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
All its trials on ClinicalTrials.gov, any status12
- Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
- A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
- Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)11
- A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.
- Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.
- The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study.
- A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.
- A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).
- Abstract CT274: BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as firs
- 203P Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
- Neoadjuvant tislelizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis of a phase 2 study.
- Neoadjuvant pembrolizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim results.
- A Novel Potential Diagnostic and Prognostic Biomarker for Esophageal Cancer
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
Cancer
Hepatocellular carcinoma
肝细胞癌Led 65 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
17 hospitals in Beijing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 19
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Recruiting68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT07590336
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingLenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07639138
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNeoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07014150
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT07157969
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Recruitingβ-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07317414
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou
- RecruitingIrreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07832006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingCadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06215651
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingCombination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06363006
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingAn Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT07101237
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingAdjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06041490
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07479485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingNWRD06 DNA Plasmid for HCC After Curative Resection.
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07324304
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led65
- Genetic Adaptation to Tibetan High Altitude and Hepatocellular Cancer Risk: Integrative Bidirectional Mendelian Randomization and Single-Cell RNA Sequencing Analysis.
- Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.
- RAD54L Is a Prognostic Biomarker and Demonstrate Correlation With Drug Sensitivity in Hepatocellular Carcinoma.
- Lung cancer associated transcript 1 binds heat shock protein 90 to promote growth of hepatocellular carcinoma.
- Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
- PAFAH1B3 Exists in Linear Chromosomal and Extrachromosomal Circular DNA and Promotes HCC Progression via EMT.
- FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.
- A Multi-phase CT Dataset for Automated Differential Diagnosis of Liver Tumors.
- MR Imaging Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: Is Radiomics Truly Helpful?
- Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.
- Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.
- HCCDB v2.0: Decompose Expression Variations by Single-cell RNA-seq and Spatial Transcriptomics in HCC.
- Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis.
- Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
- POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma.
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
- Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
- Liver fibrosis as a predictor of liver failure and outcome following ALPPS among patients with primary liver cancer.
- Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.
- Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards.
- CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
- Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination.
- Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
- Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor:
- Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
- Letter to the Editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
- Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
- Letter to the Editor: Is eliminating METTL1-mediated accumulation of PMN-MDSCs sufficient to prevent hepatocellular carcinoma recurrence after radiofrequency ablation?
- Letter to the editor: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage HCC.
- Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
- An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
- The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.
- Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib.
- Classification of metastatic hepatic carcinoma and hepatocellular carcinoma lesions using contrast-enhanced CT based on EI-CNNet.
- B4GALNT1 promotes carcinogenesis by regulating epithelial-mesenchymal transition in hepatocellular carcinoma based on pan-cancer analysis.
- Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
- Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.
- A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
- Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma.
- Letter to the editor: Liver transarterial chemoembolization plus sunitinib for unresectable hepatocellular carcinoma.
- MRI-based radiomics distinguish different pathological types of hepatocellular carcinoma.
- Letter to editor: How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?
- Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
- Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors.
- An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection.
- Diagnostic and prognostic potential of methylated septin 9 needs more evidence in hepatocellular carcinoma.
- Research progress and prospects of circulating tumor cells in hepatocellular carcinoma.
- Letter to the editor: Cautious use of multistate modeling in prognosis analysis of HCC.
- Letter to the Editor: Inflammation influences the prognosis of hepatocellular carcinoma.
- HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
- Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.
- Dynamic 18F-FDG PET imaging of liver lesions: evaluation of a two-tissue compartment model with dual blood input function.
- Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine.
- Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma.
- An ectopic adrenocortical oncocytic adenoma in the liver highly mimicking hepatocellular carcinoma: case report and literature review.
- Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.
- Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma.
- Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study.
- Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules.
- Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
- Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients.
- Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data.
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
- Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.
- Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status48
- 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
- β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
- Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
- An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
- Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
- Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
- A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
- Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma
- Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
- Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
- Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
- Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
- Hepatobiliary Tumors Tissue Samples Acquisition
- Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
- FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
- 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma
- Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
- A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support
- Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
- Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- NWRD06 DNA Plasmid for HCC After Curative Resection.
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
- A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Cancer
Stomach cancer
胃癌Led 54 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou
- RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07114601
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led54
- IRAK1 promotes gastric cancer progression by activating the PI3K/AKT/mTOR pathway and inducing the M2 polarization of tumor-associated macrophages.
- TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation.
- Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.
- Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.
- Sarcopenic obesity exacerbates gastric cancer prognosis via increased intermuscular and visceral fat accumulation.
- Innate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis.
- CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.
- POSTN+ Cancer-Associated Fibroblasts Promote Gastric Cancer Invasion by Activating AKT Signaling.
- Treatment strategies for patients with HER2-positive gastric cancer.
- Burden of six major types of digestive system cancers globally and in China.
- Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
- Preoperative H. pylori Eradication Therapy Facilitates Precise Delineation in Early Gastric Cancer with Current H. pylori Infection.
- Profound postinduction hypotension precipitated by immune checkpoint inhibitors: a case report.
- Quercetin promotes ATG5-mediating autophagy-dependent ferroptosis in gastric cancer.
- A puzzling case report of well-differentiated neuroendocrine tumor mixed with gastric adenocarcinoma of the fundic gland type associated with autoimmune gastritis.
- Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.
- Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.
- Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019.
- Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.
- Tumour-associated macrophages in gastric cancer: From function and mechanism to application.
- Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway.
- Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study.
- [68Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI/CT: a meta-analysis.
- Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer.
- The Roles of Innate Lymphoid Cells in the Gastric Mucosal Immunology and Oncogenesis of Gastric Cancer.
- Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.
- Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis.
- Perioperative Enteral Immunonutrition Support for the Immune Function and Intestinal Mucosal Barrier in Gastric Cancer Patients Undergoing Gastrectomy: A Prospective Randomized Controlled Study.
- Association between Plasma FGF21 Levels and Body Composition in Patients with Gastric Cancer.
- Dermoscopy and high-frequency ultrasound provide diagnostic clues in a gastric adenocarcinoma with cutaneous metastasis as the initial presentation: A case report.
- Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
- Clinicopathological features, endoscopic features, and treatment analysis of gastric neuroendocrine neoplasms.
- Endoscopic characteristics in predicting prognosis of biopsy-diagnosed gastric low-grade intraepithelial neoplasia.
- Small molecules as potential biomarkers of early gastric cancer: A mass spectrometry imaging approach.
- Characterization of the fecal microbiota in gastrointestinal cancer patients and healthy people.
- Gastroblastoma Treated by Endoscopic Submucosal Excavation with a Novel PTCH1::GLI2 Fusion: A Rare Case Report and Literature Review.
- Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer.
- Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study.
- Appendiceal Neuroendocrine Tumor Is a Rare Cause of Ectopic Adrenocorticotropic Hormone Syndrome With Cyclic Hypercortisolism: A Case Report and Literature Review.
- Visceral Adipose Tissue Assessment Enhances the Prognostic Value of GLIM Criteria in Patients with Gastric Cancer Undergoing Radical Gastrectomy after Neoadjuvant Treatment.
- Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer.
- High incidence combination of multiple primary malignant tumors of the digestive system.
- Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
- CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer.
- Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
- Changes in gastric mucosal microbiota in gastric carcinogenesis: a systematic review protocol.
- Serum phospholipids are potential biomarkers for the early diagnosis of gastric cancer.
- Feasibility of standardized procedures of white light gastroscopy for clinical practice: A multicenter study in China.
- Gastrointestinal: Massive gastric juvenile polyposis.
- Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study.
- Impact of body composition on clinical outcomes in people with gastric cancer undergoing radical gastrectomy after neoadjuvant treatment.
- Gastric Cancer Cell-Derived Exosomes Can Regulate the Biological Functions of Mesenchymal Stem Cells by Inducing the Expression of Circular RNA circ_0004303.
- Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?
- Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status21
- Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting
- 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
- Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
- Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy
- An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
- FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
- Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric Cancer
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
Cancer
Retinoblastoma
视网膜母细胞瘤Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Beijing for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Osteosarcoma
骨肉瘤Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
37 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Chromoanagenesis in Osteosarcoma.
- Fine-needle aspiration cytology for the diagnosis of ewing's sarcoma in bone: a case report.
- A Se Nanoparticle/MgFe-LDH Composite Nanosheet as a Multifunctional Platform for Osteosarcoma Eradication, Antibacterial and Bone Reconstruction.
- An update on the roles of circular RNAs in osteosarcoma.
Earlier papers (2016–2020)8
- Identification of the Novel Target Genes for Osteosarcoma Therapy Based on Comprehensive Bioinformatic Analysis.
- LINC01133: an emerging tumor-associated long non-coding RNA in tumor and osteosarcoma.
- Isolated diaphragmatic metastasis from periosteal osteosarcoma of the humerus: a case report.
- The long non-coding RNA SPRY4-IT1: An emerging player in tumorigenesis and osteosarcoma.
- SPOCD1 promotes cell proliferation and inhibits cell apoptosis in human osteosarcoma.
- TRIM59 is upregulated and promotes cell proliferation and migration in human osteosarcoma.
- Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.
- Long non-coding RNAs: emerging players in osteosarcoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 6 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Heterotopic Pancreas Mimicking Gastrointestinal Stromal Tumor on 68 Ga-NOTA-RM26 PET/CT.
- Unraveling the site-specific features in small intestinal stromal tumors: a retrospective study.
- Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.
- Three-dimensional bioprinting of patient-derived Gastrointestinal stromal tumor: a novel platform for precision oncology and drug response profiling.
- Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study.
- Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance.
Earlier papers (2016–2020)10
- Ectopic bronchogenic cyst of the gastric cardia considered to be a gastrointestinal stromal tumor before surgery: a case report.
- Retroperitoneal fibromatosis presenting as a mesenteric mass: A case report.
- Short- and Long-Term Outcomes of Endoscope-Assisted Laparoscopic Wedge Resection for Gastric Submucosal Tumors Adjacent to Esophagogastric Junction.
- Transanal Endoscopic Microsurgery for Patients with Rare Rectal Tumors.
- [Transanal endoscopic microsurgery for local excision of rectal gastrointestinal stromal tumors].
- A Novel Curative Treatment Strategy for Patients with Lower Grade Rectal Gastrointestinal Stromal Tumor: Chemoreduction Combined with Transanal Endoscopic Microsurgery.
- Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: A case report.
- Comparison of short- and long-term outcomes of laparoscopic vs open resection for gastric gastrointestinal stromal tumors.
- Ghrelin and gastrointestinal stromal tumors.
- [Rectal gastrointestinal stromal tumor: a clinical and pathologic analysis].
All its trials on ClinicalTrials.gov, any status2
Cancer
Neuroblastoma
神经母细胞瘤Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for neuroblastoma321 hospitals in China for neuroblastoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Recruiting18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
- Phase
- Early phase 1
- Started
- 2021-09
- Registry
- NCT05069220
Age 1 year to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Global time-trend analysis and projections of disease burden for neuroblastic tumors: a worldwide study from 1990 to 2021.
- 18 F-MFBG PET/CT and MRI in Identifying Brain Metastases in a Posttreatment Neuroblastoma Patient.
- [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.
- B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
- Shear wave elastography for differentiating parathyroid neoplasms with malignant diagnosis or uncertain malignant potential from parathyroid adenomas: initial experience.
- Oncogene or tumor suppressor gene: An integrated pan-cancer analysis of NBPF1.
- Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Beijing for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.
14 hospitals in Beijing for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 8
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingIsa-VRD in TIE HRMM
- Phase
- Phase 4
- Started
- 2026-01
- Registry
- NCT07334535
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingApplication Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
- Phase
- N/A
- Started
- 2026-02
- Registry
- NCT07353554
Age 18 years to 85 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07663253
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingRisk Stratification and MRD-driven Maintenance for MM After ASCT
- Phase
- N/A
- Started
- 2024-12
- Registry
- NCT06697483
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led27
- Total tumor apparent diffusion coefficient histogram analysis of whole-body DWI-MRI for prognostic stratification in patients with R-ISS stage II multiple myeloma.
- Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
- Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.
- Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab.
- Total Tumor ADC Histogram Analysis: A New Tool for Predicting High-Risk Cytogenetic Abnormalities in Multiple Myeloma Patients.
- Myc rearrangement redefines the stratification of high-risk multiple myeloma.
- M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
- Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
- MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.
- Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.
- Impaired acute-phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS-CoV-2 Omicron variants outbreak infection.
- BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
- Treatment Response Assessment in Multiple Myeloma: Histogram Analysis of Total Tumor Apparent Diffusion Coefficient based on Whole-body Diffusion-weighted MR Imaging.
- Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone.
- Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.
- A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD.
- Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.
- Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System.
- 68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles.
- Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.
- A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.
- The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
- Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
- Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma.
- Multiple myeloma complicated by skull plasmacytoma discovered after head injury.
- 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
- Gastric Cancer or Plasmacytoma in a Seemingly Well-Controlled Multiple Myeloma Patient?
Chinese-language papers (not in the count)9
- [Value of gene mutation in the prognosis and treatment of multiple myeloma].
- [The 505th case: refractory ascites and monoclonal immunoglobulin].
- [Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone].
- [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].
- [The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment].
- [A case of multiple myeloma accompanied with breast cancer and lung cancer].
- [Chronic myelomonocytic leukemia accompanied with multiple myeloma: a case report].
- [Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].
- [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
All its trials on ClinicalTrials.gov, any status35
- Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
- Isa-VRD in TIE HRMM
- Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
- 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
- Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
- Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
- Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Risk Stratification and MRD-driven Maintenance for MM After ASCT
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- A Study of Ninlaro in Real World Clinical Practice in China
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
- Ixazomib Rollover Study
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06481735
Age 16 years to 70 years (registered criteria)
Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 16 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 3.9%.
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT06802055
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led16
- Exploration of B- and T-Cell Receptor Repertoires Reveals Distinct Mechanisms in Pure Red Cell Aplasia, Autoimmune Hemolytic Anemia, and Aplastic Anemia.
- Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China.
- Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.
- Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.
- Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study.
- Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study.
- High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study.
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.
- Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial.
- Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers.
- Plasma lipidome acts as diagnostic marker and predictor for cyclosporin response in patients with aplastic anemia.
- Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study.
- Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study.
- Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag.
- Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
- Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A.
Chinese-language papers (not in the count)4
- [Efficacy and safety of lusutrombopag monotherapy for cyclosporine A-refractory, transfusion-dependent non-severe aplastic anemia].
- [Efficacy and safety of roxadustat in the treatment of refractory non-severe aplastic anemia].
- [Clinical characteristics and prediction model of early death in severe/very severe aplastic anemia with immunosuppressive therapy].
- [Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells].
All its trials on ClinicalTrials.gov, any status19
- Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
- Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA
- A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA
- Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
- Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
- A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
- CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
- Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA
- Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System
- A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA
- Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
- Avatrombopag Usage in NSAA
- Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
- Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients
- Tacrolimus Treatment for Refractory Autoimmune Cytopenia
- Tacrolimus Treatment for Refractory PRCA
- Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
- Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
- Sirolimus Treatment for Refractory PRCA
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 7 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- CHOP is insufficient for newly-diagnosed subcutaneous panniculitis-like T-cell lymphoma patients: a retrospective study of 32 patients in China.
- Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.
- Disseminated tuberculosis complicated by intramuscular abscesses, meningoencephalitis, and hemophagocytic lymphohistiocytosis: a case report.
- Germline defects of familial hemophagocytic lymphohistiocytosis-related genes presenting as adult-onset peripheral T-cell lymphoma.
- Case Report: Missing zinc finger domains: hemophagocytic lymphohistiocytosis in a GATA2 deficiency patient triggered by non-tuberculous mycobacteriosis.
- Reversal of SLE and hemophagocytic lymphohistiocytosis caused by lysinuric protein intolerance through allogeneic hematopoietic stem cell transplantation.
- Management of hemophagocytic lymphohistiocytosis in pregnancy: Case series study and literature review.
Chinese-language papers (not in the count)3
- [Recommendations for the diagnosis and treatment of rheumatic diseases-related hemophagocytic syndrome in China].
- [Assessment of MS-Score and HScore in timeliness of diagnosis of macrophage activation syndrome associated with adult-onset Still's disease].
- [Progress of targeted therapy in macrophage activation syndrome secondary to autoimmune diseases].
All its trials on ClinicalTrials.gov, any status2
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
More papers found outside PubMed (not counted)4
- IFN-γ-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL
- CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China
- Chemo-Free Salvage Treatment Is Better Than Traditional Chemotherapy in Relapsed/Refractory Subcutaneous Panniculitis-like T-Cell Lymphoma
- Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma
Blood disorders
Beta thalassaemia
β 地中海贫血Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Haemophilia A
血友病 ALed 17 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 6.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
14 hospitals in Beijing for haemophilia A132 hospitals in China for haemophilia A
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07416604
Age 12 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingEvaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- Phase
- Phase 2/Phase 3
- Started
- 2024-01
- Registry
- NCT06111638
Age 18 years to Not stated; men only (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- Analysis of the current status and characteristics of osteoporosis in adult hemophilia patients based on high-resolution peripheral quantitative computed tomography: a case control study.
- Absence of femur induced by haemophilic pseudotumour.
- Renal inflammatory myofibroblastic tumor coexisting with hemophilia A carrier: a case report and literature review.
- Chain-mediating effects of kinesiophobia and self-efficacy on pain catastrophizing and physical activity in haemophilia patients.
- Incidence and treatment-related risk factors of inhibitor development after intensive FVIII replacement for major orthopaedic surgery in previous treated haemophilia A.
- Present status of scheduled vaccinations and vaccination-related bleeding in Chinese children with haemophilia.
- Pathogenesis and treatment of osteoporosis in patients with hemophilia.
- Long-term clinical outcomes following total knee arthroplasty in patients with hemophilic arthropathy: a single-surgeon cohort after a 10- to 17-year follow-up.
- Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.
- A Novel Surgical Classification for Extremity and Pelvic Hemophilic Pseudotumors: The PUMCH Classification.
- Replacement Therapy for Hemophilia Patients Undergoing Cardiac Surgery: Report of Three Cases.
- Risk Factors for Amputation in the Surgical Treatment of Hemophilic Osteoarthropathy: A 20-Year Single-Center Report.
- Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia.
- Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
- Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A.
- Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
- Conservative therapy for spinal epidural hematoma in a child with hemophilia A with high-titer VIII inhibitors.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)30
- Early wound complications after orthopaedic surgery for haemophilia: What can we do more.
- Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20-year single-surgeon cohort.
- Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A 6-year follow-up study.
- Bleeding assessment in haemophilia carriers-High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China.
- Hemophilic Pseudotumor.
- [Orthopedic treatment of musculoskeletal disorders in hemophilic patients].
- Survey of non-physiotherapy department medical staff in China and their understanding of physiotherapy in comprehensive management of haemophilia.
- Surgical Management of Haemophilic Pseudotumors: Experience in a Developing Country.
- Incidence of Symptomatic Venous Thromboembolism in Patients with Hemophilia Undergoing Hip and Knee Joint Replacement without Chemoprophylaxis: A Retrospective Study.
- Successful treatment of giant abdominal haemophilic pseudotumours causing hydronephrosis.
- Management of knee flexion contracture in haemophilia with the Ilizarov technique.
- [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
- Pelvi-Femoral Complete Bone Bridge in a Patient with Hemophilia.
- Application of optimized nursing process to perioperative patients with haemophilic pseudotumours.
- Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China.
- Hemophilic arthropathy in a patient with multi-joint replacement: A case report and literature review.
- Simultaneous bilateral total knee arthroplasty in patients with end-stage hemophilic arthropathy: a mean follow-up of 6 years.
- Efficacy of a modified coagulation factor substitution for total hip arthroplasty in patients with end-stage haemophilic arthropathy.
- An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
- Surgical treatment of a giant iliopsoas haemophilic pseudotumour with adjacent structure compressions: A case report.
- Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy.
- Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
- Open repair of intraoperative popliteal artery injury during total knee arthroplasty in a patient with severe hemophilia A: A case report and literature review.
- Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.
- Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
- Surgical Treatment for Hemophilic Pseudotumor: Twenty-three Cases with an Average Follow-up of 5 Years.
- Coexistence of acquired hemophilia A and epidermolysis bullosa acquisita: Two case reports and published work review.
- Moderate-intensity exercise improves the thromboelastography coagulation index in children with severe hemophilia A.
- Analyses of joint health and influencing factors in different age groups of Chinese children with haemophilia.
- Perioperative Period of a Hemophilia-related Osteoarthropathy Therapeutic Regimen and Analysis of Complications.
All its trials on ClinicalTrials.gov, any status9
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
- A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
- China ADVATE PTP Study
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)7
- Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13.
- Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab.
- Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
- First case report of bacteremia caused by Solobacterium moorei in China, and literature review.
- Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases.
- Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.
- [The 466th case:myasthenia,fever,blurred vision and pancytopenia].
All its trials on ClinicalTrials.gov, any status2
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 8 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led8
- Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.
- Neuromyelitis optica spectrum disorders with recurrent syncope due to area postrema syndrome: a case report and literature review.
- Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs.
- Retinal structural and microvascular deterioration independent of optic neuritis in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders: An optical coherence tomography angiography study.
- Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.
- Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder.
- Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity.
- Patients with neuromyelitis optica spectrum disorder (NMOSD) are associated with adverse outcome after total hip arthroplasty: a matched case-control study.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 47 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 19.1%.
11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Registry
- NCT07068165
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT07104058
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTreatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
- Phase
- N/A
- Started
- 2022-07
- Registry
- NCT05789030
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNational Registry of IgG4-RD in China
- Phase
- Not given
- Started
- 2016-12
- Registry
- NCT03023371
Age not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Prospective Cohort Study of IgG4RD in China
- Phase
- Not given
- Started
- 2012-01
- Registry
- NCT01670695
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingNebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- Phase
- Early phase 1
- Started
- 2026-10
- Registry
- NCT07806045
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- Not yet recruitingTripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07878585
Age 45 years to 79 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
- Not yet recruitingStudy to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07222553
Age 2 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led47
- Allergen-Specific IgE and IgG4 Signatures in IgG4-Related Disease Revealed by a Large-Scale PhIP-Seq Study.
- Genome-wide association studies reveal new insights into the genetic basis of IgG4-related disease in the Chinese Han population.
- Evaluating and predicting disease damage accumulation of IgG4-RD over ten years: utility of the IgG4-related Disease Damage Index.
- Elevated eosinophil-to-lymphocyte ratio (ELR) as a predictor of relapse for IgG4-related disease: a retrospective study across a decade.
- IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort.
- Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases.
- Exploring the clinical characteristics and long-term outcome of serologically active clinically quiescent IgG4-related disease: knowledge from a prospective cohort.
- Polarization of Vδ2 T cells to a Th2-like phenotype promotes plasmablast differentiation and possesses pro-fibrotic properties in IgG4-related disease.
- Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease.
- Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease.
- Clinical and Radiologic Differences in Lung Involvement Between IgG4-Related Disease and Plasma Cell-Type Idiopathic Multicentric Castleman Disease.
- Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
- Comparison of clinical features and outcomes of proliferative, fibrotic, and mixed subtypes of IgG4-related disease: A retrospective cohort study.
- Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis.
- Expansion and surface makers of age-associated B cells in IgG4-related disease.
- Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis.
- Revealing the distinct clinical patterns and relapse risk factors in seronegative IgG4-RD patients: A retrospective cohort study over a decade.
- Coronary periarteritis and pericarditis are rare but distinct manifestations of heart involvement in IgG4-related disease: a retrospective cohort study.
- The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD Consortium.
- Sex bias in IgG4-related disease: from clinical phenotype to mechanisms.
- Differential CpG DNA methylation of peripheral B cells, CD4+ T cells, and salivary gland tissues in IgG4-related disease.
- Coronary artery ectasia associated with IgG4-related disease: a case report and literature review.
- Memory CD4+T cell profile is associated with unfavorable prognosis in IgG4-related disease: Risk stratification by machine-learning.
- Prominent 68 Ga-FAPI Uptake in Renal Parenchyma Caused by Immunoglobulin G4-Related Nephropathy.
- Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.
- Confusions and challenges in the diagnosis of IgG4-related disease.
- A unified serum IgG4 cut-off level for the diagnosis of IgG4-related disease using a wide array of kits.
- Potential impact of autoimmune diseases family history in IgG4-related disease: a retrospective cohort study.
- The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China.
- Distinct metabolic biomarkers to distinguish IgG4-related disease from Sjogren's syndrome and pancreatic cancer and predict disease prognosis.
- Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study.
- Expanded CD4+CXCR5-PD-1+ peripheral T helper like cells and clinical significance in IgG4-related disease.
- Single-Cell Sequencing of Immune Cell Heterogeneity in IgG4-Related Disease.
- Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up.
- TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease.
- Human epididymis protein 4 (HE4) is a novel biomarker for fibrosis in IgG4-related disease and can predict poor prognosis.
- Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease.
- Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study.
- Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients.
- The association of different serum IgG4 levels with distinct clinical characteristics and treatment efficacy in patients with IgG4-related disease.
- Assessing serum IgG4 glycosylation profiles of IgG4-related disease using lectin microarray.
- Multiple nodules under the pericardium in a patient with IgG4-related disease.
- Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease.
- Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage.
- Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT.
- Clinical features and treatment efficacy for IgG4-related thyroiditis.
- Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status24
- Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
- National Registry of IgG4-RD in China
- A Prospective Cohort Study of IgG4RD in China
- Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period
- Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
- Belimumab Treatment for IgG4-related Disease
- Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD
- Withdraw Drug in Stable IgG4-Related Disease
- Characterizing IgG4-RD With 68Ga-FAPI PET/CT
- Leflunomide Treatment for IgG4-RD
- Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids
- Study of Treatment Response on IgG4 Related Disease (IgG4RD)
- 18F-FDG PET/CT for IgG4-Related Disease
- Glucocorticoids in Patients With IgG4-RD
- Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
- Short-term Glucocorticoid Combined with MMF for IgG4-RD
- To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
More papers found outside PubMed (not counted)16
- ABS0650 ECONOMIC BURDEN AND LIFE QUALITY OF IgG4-RELATED DISEASE IN CHINA: A COMPARATIVE ANALYSIS OF THREE TREATMENT REGIMENS
- ABS0877 FEATURES OF IgG4-RELATED SCLEROSING MESENTERITIS: DATA FROM A LARGE COHORT IN CHINA
- Malignancies and IgG4‐related disease
- OP0187 THE CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT IGG4-RELATED DISEASE: A RETROSPECTIVE STUDY
- OP0189 SAFETY AND EFFICACY OF INEBILIZUMAB IN IgG4-RELATED DISEASE ACROSS VARIOUS PARTICIPANT DEMOGRAPHICS: SUBGROUP ANALYSIS FROM THE MITIGATE STUDY
- POS0009 Early Onset and Durability of Efficacy in Inebilizumab-treated Participants with IgG4 Related Disease: Post Hoc Analyses from the Phase 3 MITIGATE Trial
- POS0647 ASSOCIATION OF TREATING STRATEGY ADJUSTMENT FOR IgG4-RD RELAPSE AND RECURRENT RELAPSE: LESSONS FROM A PROSPECTIVE COHORT
- Safety and efficacy of inebilizumab in IgG4 related disease in participants with pancreatic and biliary involvement: Results from the phase 3 mitigate trial
- Single-cell multi-omics analysis revealed the expansion of age-associated B cells in the pancreas of type 1 autoimmune pancreatitis patients
- CT findings of IgG4-related thoracic disease: correlations with clinical and laboratory characteristics
- Comparison of clinical and radiological features of lung involvement between IgG4-related disease and idiopathic multicentric Castleman disease
- IgG4-Related Disease
- Integrative analysis reveals the role of THBS1 in IgG4-related disease
- Additional file 3 of TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease
- Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity
- Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases
Other diseases
Myasthenia gravis
重症肌无力Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.
- Open trials led
- 0
- recruiting or about to
11 hospitals in Beijing for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Comorbidity of Myasthenia gravis and Graves' disease as immune reconstitution-associated autoimmune disease in HIV infection: A case report and literature review.
- Iron metabolism in non-anemic myasthenia gravis patients: A cohort study.
- Combined effect of thymectomy on myasthenia gravis in patients with concomitant auto-immune diseases: a 22-year single-center experience.
- Severe complications and management of a patient with myasthenia gravis undergoing anterior cervical spinal surgery: a case report.
- Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.
- Surgical treatment is effective in treating thymoma accompanied with non-myasthenia gravis autoimmune diseases: a single-center clinical experience.
All its trials on ClinicalTrials.gov, any status4
- A Prospective Cohort Study of Myasthenia Gravis in China
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 9 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 2.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led9
- Combining machine learning with external validation to explore necroptosis and immune response in moyamoya disease.
- Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Moyamoya Disease.
- Recent Advances in Genetics of Moyamoya Disease: Insights into the Different Pathogenic Pathways.
- Correlation between collateral compensation of the posterior cerebral artery on 5 T magnetic resonance imaging and clinical classifications in patients with Moyamoya angiopathy.
- 5.0T MRA techniques for evaluating Moyamoya disease: 4D-ASL-MRA vs. 3D-TOF-MRA.
- Single-Cell Transcriptome Profiling Reveals Dynamic Cell Populations and Immune Infiltration in Moyamoya Disease.
- Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.
- Machine learning identifies KRT8 dysregulation and endothelial remodeling in Moyamoya disease.
- RNF213 in moyamoya disease: Genotype-phenotype association and the underlying mechanism.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)3
- Abstract TP382: Genome-wide DNA Methylation Profiling Reveals Low Methylation Variability in Moyamoya Disease
- RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease
- Correlation Analysis of Middle Cerebral Artery Stenosis and Enlarged Perivascular Space in Patients with Moyamoya Disease (S45.007)
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Abundant infiltration of B cells and plasma cells in brain biopsy of a male patient with severe anti-NMDA receptor encephalitis: A case report.
- Anti-N-methyl-D-aspartate receptor encephalitis: characteristics and rapid diagnostic approach in the emergency department.
- The changing spectrum of antibody-mediated encephalitis in China.
Earlier papers (2016–2020)12
- Electroencephalogram and Clinical Characteristics and Correlations in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.
- Anti-NMDAR encephalitis: A single-center, longitudinal study in China.
- [Neuropsychiatric symptoms and caregivers' distress in anti-N-methyl-D-aspartate receptor encephalitis].
- Surgical outcomes in patients with anti-N-methyl D-aspartate receptor encephalitis with ovarian teratoma.
- Nursing care in anti-N-methyl-D-aspartate receptor encephalitis: A case series.
- Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study.
- Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
- Resection of melanocytic nevi as a potential treatment of anti-NMDAR encephalitis patients without tumor: report of three cases.
- [Analysis of prodromal phase and prodromal events in anti-N-methyl-D-aspartate receptor encephalitis].
- Treatment principles of ovarian teratoma with anti-N-methyl-D-aspartate receptor encephalitis.
- Changing Brain Metabolism Patterns in Patients With ANMDARE: Serial 18F-FDG PET/CT Findings.
- [Immunotherapy strategy for 35 cases of severe anti-N-methyl-D-aspartate receptor encephalitis].
Other diseases
Takayasu arteritis
大动脉炎Led 27 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 14.4%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led27
- Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis.
- Exosome miR-199a-5p modulated vascular remodeling and inflammatory infiltration of Takayasu's arteritis.
- Optimizing ultrasound evaluation of carotid artery stenosis in Takayasu's Arteritis: a focus on residual inner diameter as a key parameter.
- Downregulated Expression of miR-200c-3p in Plasma Exosome as a Potential Biomarker in Takayasu's Arteritis.
- Validation and clinical application of 2022 ACR/EULAR criteria for Takayasu arteritis in a large Chinese cohort.
- Predictors of Cardiovascular Events in Patients With Takayasu Arteritis.
- Association between premature vascular smooth muscle cells senescence and vascular inflammation in Takayasu's arteritis.
- Phenotype of Takayasu-like vasculitis and cardiopathy in patients with Blau syndrome.
- Incidence, risk factors for active tuberculosis infection and changes of IGRA in patients with Takayasu arteritis: a prospective cohort study.
- Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis.
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.
- Dark-Blood Computed Tomography Angiography Combined With Deep Learning Reconstruction for Cervical Artery Wall Imaging in Takayasu Arteritis.
- Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.
- Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis.
- The performance of duplex ultrasonography for the assessment of renal artery stenosis in Takayasu's arteritis patients.
- Percutaneous transluminal pulmonary angioplasty for Takayasu arteritis-associated pulmonary hypertension: A single-arm meta-analysis.
- Predictors of relapse in Takayasu arteritis.
- Altered glycosylation profiles of serum IgG in Takayasu arteritis.
- Isolated Coronary Arteritis in Adults: a Single-Center Experience from China.
- Ultrasonography and contrast-enhanced ultrasound for activity assessment in 115 patients with carotid involvement of Takayasu arteritis.
- Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension.
- Pregnancy outcomes in Takayasu arteritis patients.
- Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu's arteritis patients.
- Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study.
- Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis.
- Clinical Features and Risk Factors for Active Tuberculosis in Takayasu Arteritis: A Single-Center Case-Control Study.
- Identification of Novel Serological Autoantibodies in Takayasu Arteritis Patients Using HuProt Arrays.
Chinese-language papers (not in the count)4
- [Correlation between soluble CD146 and systemic vasculitis].
- [To improve the prognosis in patients with Takayasu's arteritis by standardized the diagnosis and treatment in China].
- [Analysis of differentially expressed microRNA and protein expression profiles carried by exosomes in the plasma of patients with Takayasu's arteritis].
- [Recommendations of diagnosis and treatment of Takayasu's arteritis in China].
Earlier papers (2016–2020)23
- An Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences.
- Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu's arteritis patients.
- Impact of coronary involvement on long-term outcomes in patients with Takayasu's arteritis.
- Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients.
- Response to letter to the editor on "Percutaneous coronary intervention underperforms in Takayasu Arteritis".
- Comparing the effects of different management strategies on long-term outcomes for significant coronary stenosis in patients with Takayasu arteritis.
- Tofacitinib in patients with refractory Takayasu's arteritis.
- Takayasu Arteritis With Coronary Artery Involvement: Differences Between Pediatric and Adult Patients.
- Pulmonary artery involvement in Takayasu's arteritis: diagnosis before pulmonary hypertension.
- Study on the association of serum pentraxin-3 and lysosomal-associated membrane protein-2 levels with disease activity in Chinese Takayasu's arteritis patients.
- Diffuse aortoiliac occlusion with formation of extensive collateral circulation in Takayasu's arteritis.
- The octopus on a heart.
- Tuberculosis Infection in Chinese Patients with Giant Cell Arteritis.
- Association between genetic variants in the human leukocyte antigen-B/MICA and Takayasu arteritis in Chinese Han population.
- The renal artery is involved in Chinese Takayasu's arteritis patients.
- [The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].
- The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years.
- The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis.
- Takayasu arteritis presented with acute heart failure: case report and review of literature.
- Association of FCGR2A/FCGR3A variant rs2099684 with Takayasu arteritis in the Han Chinese population.
- Single nucleotide polymorphisms of IL12B are associated with Takayasu arteritis in Chinese Han population.
- Cause of death in Chinese Takayasu arteritis patients.
- The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis.
All its trials on ClinicalTrials.gov, any status6
- Pulmonary Artery Involvement in Takayasu's Arteritis
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
- The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
- Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis
- Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Other diseases
Hepatic echinococcosis
肝包虫病Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 18 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.8%.
- Open trials led
- 0
- recruiting or about to
25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
- RecruitingSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 2/Phase 3
- Started
- 2023-06
- Registry
- NCT06125327
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led18
- Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.
- Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.
- Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses.
- Transcriptomic and network analysis identifies shared and unique pathways and immune changes across fibrotic interstitial lung diseases.
- The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis.
- Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes.
- Interstitial lung diseases associated with ANCA positivity: A different disease spectrum from interstitial pneumonia with autoimmune features.
- FSTL1 promotes alveolar epithelial cell aging and worsens pulmonary fibrosis by affecting SENP1-mediated DeSUMOylation.
- Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment.
- SENP1 regulates the transformation of lung resident mesenchymal stem cells and is associated with idiopathic pulmonary fibrosis progression.
- Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling.
- Endoplasmic reticulum stress modulates the fate of lung resident mesenchymal stem cell to myofibroblast via C/EBP homologous protein during pulmonary fibrosis.
- CCAAT/enhancer-binding protein (C/EBP) homologous protein promotes alveolar epithelial cell senescence via the nuclear factor-kappa B pathway in pulmonary fibrosis.
- Regulation of the IGF1 signaling pathway is involved in idiopathic pulmonary fibrosis induced by alveolar epithelial cell senescence and core fucosylation.
- Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review.
- Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.
- Whole-exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis in the Chinese population.
Chinese-language papers (not in the count)5
- [Recomment of the correctly understand and standardize the use of terms and concepts related to interstitial lung disease].
- [Update in interstitial lung disease 2024].
- [Update in interstitial lung disease 2023].
- [Clinical analysis of autoimmune diseases associated with interstitial lung diseases initially presented with idiopathic pulmonary fibrosis].
- [Update in interstitial lung disease 2021].
Earlier papers (2016–2020)12
- The Association Between MUC5B Mutations and Clinical Outcome in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Retrospective Exploratory Study in China.
- Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
- Relation between sex hormones and leucocyte telomere length in men with idiopathic pulmonary fibrosis.
- Clinicopathological characteristics of lung cancer in patients with systemic sclerosis.
- [The clinical features and prognosis of interstitial lung disease patients with positive anti-neutrophil cytoplasmic antibody].
- Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.
- [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].
- [The role of histone deacetylases in the pathogenesis of idiopathic pulmonary fibrosis and cryptogenic organizing pneumonia].
- [The role of B cell activating factor in the differential diagnosis of usual interstitial pneumonia].
- A CARE-compliant case report: Lung transplantation for a Chinese young man with idiopathic pleuroparenchymal fibroelastosis.
- Association between nonspecific interstitial pneumonia and presence of CD20+ B lymphocytes within pulmonary lymphoid follicles.
- Organizing pneumonia components in non-specific interstitial pneumonia (NSIP): a clinicopathological study of 33 NSIP cases.
All its trials on ClinicalTrials.gov, any status19
- 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
- Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 14 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 31.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led14
- Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort.
- Associations of VEGF-D levels with clinical manifestations in lymphangioleiomyomatosis: a cross-sectional analysis of 631 cases.
- Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells.
- Omics research in lymphangioleiomyomatosis: status and challenges.
- Intraoperative mechanical ventilation and incidence of pneumothorax in lymphangioleiomyomatosis.
- Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report.
- Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
- Gene mutations in sporadic lymphangioleiomyomatosis and genotype-phenotype correlation analysis.
- Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study.
- Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.
- The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis.
- 68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy: a prospective study.
- The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic.
- Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM).
Earlier papers (2016–2020)13
- Lymphangioleiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT.
- Usefulness of 99mTc-ASC lymphoscintigraphy and SPECT/CT in the evaluation of rare lymphatic disorders: Gorham-Stout disease, lymphangioma, and lymphangioleiomyomatosis.
- Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study.
- Kaposiform lymphangiomatosis with spinal involvement.
- Lymphangioleiomyomatosis.
- Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
- Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.
- Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
- The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
- Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
- Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage.
- Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma.
- Diffuse Cystic Lung Diseases: Diagnostic Considerations.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 44 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 5.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led44
- Impacts of oral supplementation of vitamin B12 and plasma levels of homocysteine on progression and survival in a Chinese ALS cohort.
- Gain-of-function ANXA11 mutation cause late-onset ALS with aberrant protein aggregation, neuroinflammation and autophagy impairment.
- Exploring oculomotor challenges in amyotrophic lateral sclerosis: a comprehensive review.
- The Impact of Bulbar and Upper Motor Neuron Involvement on Oculomotor Movement in Amyotrophic Lateral Sclerosis.
- Lead exposure induces ferroptosis in ALS cell models by activating the MAPK/ERK signaling pathway.
- Fasciculation in limbs serves as the predictor of ALS progression: an ultrasound study.
- The Inflammatory Puzzle: Piecing together the Links between Neuroinflammation and Amyotrophic Lateral Sclerosis.
- Genotype-phenotype association and functional analysis of hnRNPA1 mutations in amyotrophic lateral sclerosis.
- Neuromuscular ultrasound in combination with nerve conduction studies helps identify inflammatory motor neuropathies from lower motor neuron syndromes.
- Dysregulated N6-methyladenosine modification in peripheral immune cells contributes to the pathogenesis of amyotrophic lateral sclerosis.
- Clinical and genetic characteristics of 1672 cases of amyotrophic lateral sclerosis in China: a single-center retrospective study.
- The prognostic value of systematic genetic screening in amyotrophic lateral sclerosis patients.
- Development of novel treatments for amyotrophic lateral sclerosis.
- Incidence of amyotrophic lateral sclerosis-associated genetic variants: a clinic-based study.
- Split Phenomenon of Fasciculation between Antagonistic Muscles in Amyotrophic Lateral Sclerosis: An Ultrasound Study.
- Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
- The Serotonergic System and Amyotrophic Lateral Sclerosis: A Review of Current Evidence.
- A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis.
- The cross-sectional area of peripheral nerve in amyotrophic lateral sclerosis: A case-control study.
- The level of homocysteine in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
- Association of apolipoprotein E ε4 allele and amyotrophic lateral sclerosis in Chinese population.
- Slow progression of amyotrophic lateral sclerosis in a Chinese patient carrying SOD1 p.S135T mutation.
- Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis.
- Brain structural and perfusion changes in amyotrophic lateral sclerosis-frontotemporal dementia patients with cognitive and motor onset: a preliminary study.
- Association between abnormal expression and methylation of LGALS1 in amyotrophic lateral sclerosis.
- Epigenome-wide DNA methylation study of whole blood in patients with sporadic amyotrophic lateral sclerosis.
- Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.
- Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review.
- Genotype-phenotype association of TARDBP mutations in Chinese patients with amyotrophic lateral sclerosis: a single-center study and systematic review of published literature.
- Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.
- Survival analysis of clinical and genetic factors in an amyotrophic lateral sclerosis cohort from China.
- Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- Blood-brain barrier dysfunction and myelin basic protein in survival of amyotrophic lateral sclerosis with or without frontotemporal dementia.
- Mutation spectrum of chinese amyotrophic lateral sclerosis patients with frontotemporal dementia.
- Clinical characteristics and prognosis of amyotrophic lateral sclerosis with autoimmune diseases.
- Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis.
- Mutations of DNAJC7 are rare in Chinese amyotrophic lateral sclerosis patients.
- Fasciculation differences between ALS and non-ALS patients: an ultrasound study.
- Split hand in amyotrophic lateral sclerosis: A systematic review and meta-analysis.
- Authors' reply: Four novel optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in Mainland China.
- Four novel optineurin mutations in patients with sporadic amyotrophic lateral sclerosis in Mainland China.
- Split phenomenon of antagonistic muscle groups in amyotrophic lateral sclerosis: relative preservation of flexor muscles.
- The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)28
- A prospective study on split-hand index as a biomarker for the diagnosis of amyotrophic lateral sclerosis.
- Strategy for screening cognitive impairment in Chinese patients with amyotrophic lateral sclerosis.
- Split-hand index in amyotrophic lateral sclerosis: an F-wave study.
- Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis.
- Triple Stimulation Technique in Amyotrophic Lateral Sclerosis.
- Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis.
- Environmental risk factors and amyotrophic lateral sclerosis (ALS): A case-control study of ALS in China.
- Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients.
- Monitoring Value of Multimodal Magnetic Resonance Imaging in Disease Progression of Amyotrophic Lateral Sclerosis: A Prospective Observational Study.
- Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis.
- Excessive daytime sleepiness in Chinese patients with sporadic amyotrophic lateral sclerosis and its association with cognitive and behavioural impairments.
- Mutation screening of NEK1 in Chinese ALS patients.
- Genetic analysis of TIA1 gene in Chinese patients with amyotrophic lateral sclerosis.
- Screening of GLE1 mutations in Chinese amyotrophic lateral sclerosis patients.
- [Resting-state functional MRI studies of amyotrophic lateral sclerosis patients with various levels of cognitive impairment].
- Familial Early-Onset Paget's Disease of Bone Associated with a Novel hnRNPA2B1 Mutation.
- Military service and the risk of amyotrophic lateral sclerosis: A meta-analysis.
- The Awaji criteria increases the diagnostic sensitivity of the revised El Escorial criteria for amyotrophic lateral sclerosis diagnosis in a Chinese population.
- [Sample size for the estimation of F-wave parameters in healthy volunteers and amyotrophic lateral sclerosis patients].
- H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression.
- Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin.
- Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin.
- Quantitating Changes in Jitter and Spike Number Using Concentric Needle Electrodes in Amyotrophic Lateral Sclerosis Patients.
- Pattern Differences of Small Hand Muscle Atrophy in Amyotrophic Lateral Sclerosis and Mimic Disorders.
- Mutation spectrum of Chinese patients with familial and sporadic amyotrophic lateral sclerosis.
- The distinctive genetic architecture of ALS in mainland China.
- Identification of a novel loss-of-function C9orf72 splice site mutation in a patient with amyotrophic lateral sclerosis.
- Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS.
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led 3 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 5.5%.
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07444476
Age 15 years to 60 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China.
- A perioperative nursing care protocol for patients with spinal muscular atrophy (SMA) type II or type III undergoing spinal surgery: a 4-year experience in 24 patients.
- Unilateral interlaminar fenestration on the convex side provides a reliable access for intrathecal administration of nusinersen in spinal muscular atrophy: a retrospective study.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Antisense Oligonucleotide for Spinal Muscular Atrophy
Other diseases
Fabry disease
法布雷病Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
9 hospitals in Beijing for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Pompe disease
庞贝病Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
9 hospitals in Beijing for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07058662
Age 4 years to 9 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status6
- A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy
- A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
- Bisoprolol in DMD Early Cardiomyopathy
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
- Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
- Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Other diseases
Behçet disease
白塞病Led 49 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 20.0%.
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for Behçet disease139 hospitals in China for Behçet disease
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingBaricitinib in the Treatment of Intestinal Behçet's Syndrome
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06849908
Age 18 years to 65 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05845723
Age 18 years to 65 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led49
- The clinical features, pathological findings, and risk factors of intracardiac thrombus in Behçet's syndrome.
- Artificial Intelligence-Driven Proteomics Identifies Plasma Protein Signatures for Diagnosis and Stratification of Behçet's Disease.
- The efficacy and safety of monoclonal anti-TNF antibodies in the treatment of vascular Behçet's syndrome: A systematic review and meta-analysis.
- Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis.
- Clinicopathological characteristics of severe aortic valve regurgitation caused by Behçet's syndrome.
- Evaluation of inflammatory-thrombosis panel as a diagnostic tool for vascular Behçet's disease.
- Systemic vasculitis with latent tuberculosis infection and associated factors: a cross-sectional multicenter study.
- Association between COVID-19 infection and uveitis flare in patients with Behcet's disease, a retrospective multicenter cohort study.
- Optimal timing of surgical treatment for Behcet's disease aortic or peripheral artery pseudoaneurysms.
- Defective neutrophil-derived exosomes facilitate macrophage activation through miR-122-5p in Behçet's disease.
- Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet's disease uveitis.
- Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet's disease.
- Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis.
- Endovascular repair with a physician-modified fenestrated endograft to treat abdominal aortic pseudoaneurysm with Behcet's disease: a case report.
- TNF inhibitors target a mevalonate metabolite/TRPM2/calcium signaling axis in neutrophils to dampen vasculitis in Behçet's disease.
- Behçet Disease Periaortic Pseudoaneurysms Connect with Pulmonary Artery.
- Shelterin dysfunction promotes CD4+ T cell senescence in Behçet's disease.
- Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou et al.
- Proteomics Landscape Mapping of Organ-Resolved Behçet's Disease Using In-Depth Plasma Proteomics for Identifying Hyaluronic Binding Protein 2 Expression Associated With Vascular Involvement.
- Giant coronary aneurysm of Behcet's disease with sudden syncope: a case report.
- Infectious agents and pathogenesis of Behçet's disease: An extensive review.
- Baricitinib for the treatment of refractory vascular Behçet's disease.
- Myelin basic protein and index for neuro-Behçet's disease.
- Baricitinib for the treatment of intestinal Behçet's disease: A pilot study.
- Long Term Outcomes and Potential Risk Factors for Endovascular Repair of Aortic Pseudoaneurysms in Vascular Behçet's Disease.
- Chemokines and chemokine receptors in Behçet's disease.
- Integrated analyses delineate distinctive immunological pathways and diagnostic signatures for Behcet's disease by leveraging gene microarray data.
- Intestinal Behcet's Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents.
- Macrophage polarization toward M1 phenotype through NF-κB signaling in patients with Behçet's disease.
- Pharyngeal reconstruction for severe pharyngeal stenosis in Behçet's disease: a retrospective case series.
- The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome.
- Anti-interleukin 6 receptor antibody tocilizumab was not satisfactory for acute attack of Behçet's uveitis in three consecutive patients.
- Transcriptional analysis of neutrophils from patients with Behçet's disease reveals activation and chemotaxis of neutrophils.
- Identification of novel genes in Behcet's disease using integrated bioinformatic analysis.
- The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
- Authors Reply to Letter to the Editor - In Response To: Comment on Pei M et al.'s "Analysis of Parafoveal Microvascular Abnormalities in Behcet's Uveitis Using Projection-resolved Optical Coherence Tomographic Angiography".
- Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease.
- Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome.
- Clinical features and prognosis of patients with gastrointestinal Behçet's disease-like syndrome and myelodysplastic syndrome with and without trisomy 8.
- Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet's disease patients receiving immunomodulatory treatment.
- Increased serum level of interleukin-33 in Vogt-Koyanagi-Harada correlates with disease activity.
- Aberrant monocyte subsets in patients with Behçet's disease.
- Variation of red blood cell parameters in Behcet's disease: association with disease severity and vascular involvement.
- Anaplastic large cell lymphoma in a patient with MAGIC syndrome: a case and review of the literature.
- Novel Insights Into Gene Signatures and Their Correlation With Immune Infiltration of Peripheral Blood Mononuclear Cells in Behcet's Disease.
- Genetic Association of Interleukin 33/ST2 Polymorphisms With Behcet's Uveitis.
- Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis.
- Analysis of Parafoveal Microvascular Abnormalities in Behcet's Uveitis Using Projection-Resolved Optical Coherence Tomographic Angiography.
- Neutrophil Extracellular Traps Promote Aberrant Macrophages Activation in Behçet's Disease.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)26
- A pilot study of tofacitinib for refractory Behçet's syndrome.
- Meta-analysis of anti-Saccharomyces cerevisiae antibodies as diagnostic markers of Behçet's disease with gastrointestinal involvement.
- [Progress in interferon: A treatment of Behcet syndrome].
- [Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome].
- Behçet's disease and subacute thyroiditis after a rabies inoculation: a case report and review of the literature.
- Aberrant FcγRIIb and FcγRIII expression on monocytes from patients with Behçet's disease.
- Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences.
- Clinical Features and Risk Factors of Active Tuberculosis in Patients with Behçet's Disease.
- [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
- [Cardiologists' perceptions on Behcet's disease and its cardiovascular lesions: a single center analysis].
- [Current research on cytokine gene single nucleotide polymorphisms of Behcet's syndrome].
- [Clinical features of patients with Behcet's uveitis].
- Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet's disease.
- Coronary involvement in patients with Behçet's disease.
- Erythematous plaques and nodules with orogenital ulcerations.
- The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease.
- The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet's Disease.
- Metabolomic alterations associated with Behçet's disease.
- Expression correlates between Annexin A1 and A2 autoantibodies in patients with Behçet's disease.
- Cerebral venous sinus thrombosis in Behçet's disease: a retrospective case-control study.
- Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China.
- Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease.
- Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience.
- Association study of rs924080 and rs11209032 polymorphisms of IL23R-IL12RB2 in a Northern Chinese Han population with Behcet's disease.
- Outcomes of vascular intervention and use of perioperative medications for nonpulmonary aneurysms in Behçet disease.
- [Behcet's disease and infection].
All its trials on ClinicalTrials.gov, any status7
- Baricitinib in the Treatment of Intestinal Behçet's Syndrome
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Pathogenesis of Intestinal Behcet's Syndrome
- Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
- Golimumab for the Treatment of Refractory Behcet's Uveitis
- Tocilizumab for the Treatment of Refractory Behcet's Uveitis
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Other diseases
IgA nephropathy
IgA 肾病Led 5 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
25 hospitals in Beijing for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- New biomarkers in IgA nephropathy.
- The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
- Clinicopathological Features of Gitelman Syndrome with Proteinuria and Renal Dysfunction.
- Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis.
- The spectrum of kidney biopsy findings in Chinese HIV-infected patients.
Earlier papers (2016–2020)11
- Serum TNF-α Level Is Associated with Disease Severity in Adult Patients with Immunoglobulin A Vasculitis Nephritis.
- Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History.
- [Treatment of IgA nephropathy in the era of evidence-based medicine and personalized medicine].
- Serum Levels of Joining Chain-Containing IgA1 Are Not Elevated in Patients with IgA Nephropathy.
- [The 467th case: proteinuria, periungual fibromas, and facial steatadenomas].
- Serum levels of tumor necrosis factor alpha in patients with IgA nephropathy are closely associated with disease severity.
- Diffusional kurtosis imaging in assessing renal function and pathology of IgA nephropathy: a preliminary clinical study.
- [The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].
- The Neglected Significance of Glomerular Density as a 5-year Progression Indicator for IgA Nephropathy△.
- Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
- Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Gaucher disease
戈谢病Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Beijing for Gaucher disease40 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status5
- Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
- Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Other diseases
Osteogenesis imperfecta
成骨不全症Led 14 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 14.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Beijing for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07557446
Age 12 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led14
- TBS as a complementary tool for assessing vertebral fractures and spinal deformity in children and adolescents with osteogenesis imperfecta.
- Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta.
- Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta.
- Genotype-phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta.
- Response to Letter to the Editor From Bala and Dayal: "Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study".
- Genetic Analysis, Phenotypic Spectrum and Functional Study of Rare Osteogenesis Imperfecta Caused by CRTAP Variants.
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
- Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
- Genotypic and Phenotypic Spectrum and Pathogenesis of WNT1 Variants in a Large Cohort of Patients With OI/Osteoporosis.
- Cardiovascular abnormalities and its correlation with genotypes of children with osteogenesis imperfecta.
- Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
- The role of osteocalcin in regulation of glycolipid metabolism and muscle function in children with osteogenesis imperfecta.
- Delineation of dual molecular diagnosis in patients with skeletal deformity.
- Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
Earlier papers (2016–2020)16
- A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta.
- A novel missense mutation in P4HB causes mild osteogenesis imperfecta.
- Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta.
- Genotype-phenotype relationship in a large cohort of osteogenesis imperfecta patients with COL1A1 mutations revealed by a new scoring system.
- Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta.
- Health-related quality of life in children with osteogenesis imperfecta: a large-sample study.
- Novel Mutations in PLOD2 Cause Rare Bruck Syndrome.
- Extremely low level of serum pigment epithelium-derived factor is a special biomarker of Chinese osteogenesis imperfecta patients with SERPINF1 mutations.
- Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
- Novel Mutations in SERPINF1 Result in Rare Osteogenesis Imperfecta Type VI.
- Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.
- Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.
- Osteogenesis imperfecta type V: Genetic and clinical findings in eleven Chinese patients.
- Genotype-phenotype analysis of a rare type of osteogenesis imperfecta in four Chinese families with WNT1 mutations.
- A cryptic balanced translocation involving COL1A2 gene disruption cause a rare type of osteogenesis imperfecta.
- Two novel mutations in TMEM38B result in rare autosomal recessive osteogenesis imperfecta.
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 22 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 7.3%.
15 hospitals in Beijing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Research of Tapering UDCA in PBC Patients With a Complete Response
- Phase
- Phase 4
- Started
- 2020-01
- Registry
- NCT04650243
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive.
- Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China.
- Postpartum may be a risk factor for biochemical flares in patients with primary biliary cholangitis: A single-center experience.
- Clinical characteristics of primary biliary cirrhosis - idiopathic inflammatory myopathy overlap syndrome: A single center study.
- Glomerulonephritis in primary biliary cholangitis in China: an important complication.
- Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis.
- ChIP-seq analysis found IL21R, a target gene of GTF2I-the susceptibility gene for primary biliary cholangitis in Chinese Han.
- Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
- Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.
- Rare renal proximal tubular dysfunctions in primary biliary cholangitis.
- Genetic predisposition of the gastrointestinal microbiome and primary biliary cholangitis: a bi-directional, two-sample Mendelian randomization analysis.
- Plasma lipidomics of primary biliary cholangitis and its comparison with Sjögren's syndrome.
- CCL26 in primary biliary cholangitis - Is it a novel disease mediator?
- Low vitamin D concentrations and BMI are causal factors for primary biliary cholangitis: A mendelian randomization study.
- Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis.
- Imbalanced distribution of group 2 innate lymphoid cells (ILCs) and ILC precursors in peripheral blood of patients with primary biliary cholangitis.
- The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal survey-based study.
- Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis.
- Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients.
- CXCL12-CXCR4-Mediated Chemotaxis Supports Accumulation of Mucosal-Associated Invariant T Cells Into the Liver of Patients With PBC.
- MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-β1/smad Pathway.
- Autoimmune enteropathy and primary biliary cholangitis after proctocolectomy for ulcerative colitis: A case report and review of the literature.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)7
- Role of cell autophagy in the generation of IgM and hepatic fibrosis in primary biliary cholangitis.
- Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
- [The effect of Cathepsin S in primary biliary cholangitis].
- Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report.
- Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study.
- Therapeutic advances for primary biliary cholangitis: the old and the new.
- Association of IL12A Expression Quantitative Trait Loci (eQTL) With Primary Biliary Cirrhosis in a Chinese Han Population.
All its trials on ClinicalTrials.gov, any status5
- Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
- Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 3 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 3.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Beijing for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case-control study in China.
- Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA.
- Biliary inflammation scoring for immunoglobulin G4-related sclerosing cholangitis: an endoscopic approach with endoscopic ultrasound.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)3
- [Paying attention to the diagnosis and treatment of IgG4-related sclerosing cholangitis].
- Case report: A female case of isolated IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma.
- Poor response of initial steroid therapy for IgG4-related sclerosing cholangitis with multiple organs affected.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led 2 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 3.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hirschsprung disease
先天性巨结肠Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Beijing for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 10 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 31.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led10
- Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition).
- Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.
- Study of Urinary Protein Biomarkers in Hereditary Angioedema.
- Proactive identification of rare diseases: lessons from hereditary angioedema diagnosis using electronic medical records.
- Elevated level of circulating VEGF in Chinese patients with hereditary angioedema and its correlation with disease status.
- Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review.
- Gut microbiome alterations in hereditary angioedema.
- Long-term prophylaxis of hereditary angioedema with danazol.
- Mutation update of SERPING1 related to hereditary angioedema in the Chinese population.
- Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema.
Earlier papers (2016–2020)4
- Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey.
- The natural course of hereditary angioedema in a Chinese cohort.
- Risk factors for diagnostic delay in Chinese patients with hereditary angioedema.
- Health-related quality of life and its risk factors in Chinese hereditary angioedema patients.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Majeed syndrome
Majeed 综合征Led no English-language PubMed papers on Majeed syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Beijing for Majeed syndrome7 hospitals in China for Majeed syndrome
No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other linked evidence
- Transthyretin amyloid cardiomyopathy
- Castleman disease
- Erdheim–Chester disease
- Langerhans cell histiocytosis
- Pulmonary alveolar proteinosis
- POEMS syndrome
- Rosai–Dorfman disease
- VEXAS syndrome
- Cholecystitis
- Cholelithiasis with biliary colic
- Blue rubber bleb nevus syndrome
- Autoimmune pancreatitis
- Multiple myeloma
- Relapsing polychondritis
- Adult-onset Still disease
- Eosinophilic granulomatosis with polyangiitis
- Systemic sclerosis
- Primary Sjögren syndrome
- Cushing syndrome
- Primary aldosteronism
- Primary hyperparathyroidism
- Hypophosphatasia
- Tumor-induced osteomalacia
- Gitelman syndrome
- Sarcoidosis
- Acromegaly
- Intrahepatic cholangiocarcinoma
- Achalasia
Getting in touch
Name card to show staff or a driver
北京协和医院
Peking Union Medical College Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.